secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-08-27T23:59:59+00:00
Accession:  0001437749-25-027798
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin reports positive Annamycin AML trial: median OS 15 mos for CR, 12 mos for 2L
--------------------------------------------------------------------------------

- Phase 1b/2 MB-106 trial completed; median OS 15 months for complete remissions (n=8), 12 months for 2L efficacy evaluable (n=9).
- Median OS for ITT population (1L-7L) was 9 months, exceeding typical 4-6 months for relapsed AML.
- CR rate 36% ITT, 50% in 2L; 50% of CR subjects proceeded to bone marrow transplant; no cardiotoxicity.
- Database lock expected Sep 2025; final clinical study report in Q1 2026; Phase 3 MIRACLE trial enrolling first 45 pts.
- Authorized common shares increased from 100M to 500M effective Aug 21, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925027798/0001437749-25-027798-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925027798/mbrx20250826_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-027798

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer